Roivant Sciences Announces Dermavant Acquisition by Organon

Details

and Organon announced that Organon will acquire Dermavant, a subsidiary of Roivant, for up to $1.2 billion. The acquisition includes an upfront payment of $175 million, $75 million upon regulatory approval in atopic dermatitis, and up to $950 million for commercial milestones. Dermavant is known for its innovative dermatologic therapy, VTAMA cream, which is approved for plaque psoriasis and under review for atopic dermatitis. The transaction is expected to close in Q4 2024 and is subject to regulatory review and other customary conditions.

Items reported

Exhibits (2)

About Roivant Sciences Ltd

Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.